Drug-Drug Interaction (DDI) Study for TPN171H - Trial NCT06090123
Access comprehensive clinical trial information for NCT06090123 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Completed. The study focuses on Erectile Dysfunction. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vigonvita Life Sciences
Timeline & Enrollment
Phase 1
Jan 01, 2020
Sep 02, 2020
Primary Outcome
Cmax of TPN171H,AUC of TPN171H
Summary
The primary objective of this study was to assess the effect of rifampicin,a cytochrome P450
 3A4 enzyme (CYP3A4) induction, on the pharmacokinetics (PK) of TPN171H in chinese healthy
 male subjects ,and assess the effect of itraconazole๏ผcytochrome P450 3A4 enzyme (CYP3A4)
 induction on the PK of TPN171H in chinese healthy male subjects
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06090123
Non-Device Trial